Women were less than half of the people tested for almost all of these common medicines.

High blood pressure

losartan

About half of people with high blood pressure are women, but they were only 39% of the people in its studies.

  • 39.2%

    of the people in the studies were women

  • 57%

    of studies did not allow pregnant women

  • 0%

    looked at results for women separately

Was someone like me tested?

Choose the group that fits you.

Not one of these studies reported results separately for any of the groups below.

Barely studied

Pregnant women

57% of studies would not let pregnant women join. Only 1 small study (11 women in all) looked at pregnancy or just after birth.

What do we know?

What the FDA drug label says

Can seriously harm or kill an unborn baby, especially in the 2nd and 3rd trimesters. Stop taking it as soon as you know you are pregnant, and talk to your doctor.

Studies focused on this group (1)

What women report more

Compared with men taking the same medicine.

  • 2.2×Broken bones
  • 1.9×Bone and joint injuries
  • 1.7×Headaches
  • 1.7×Hair, nail and sweat-gland problems

How many times more often women reported each problem than men taking the same medicine, based on reports to the FDA. This is a warning sign, not proof the medicine caused it.

Make it about you

Check it against your medicines

Check losartan against the medicines, pregnancy and birth control in your profile.

Join to check

Women's experiences

Join or sign in to share, like or save. You'll fill in a short health profile so your story has context and we can check your medicines.

No one has shared yet. Your story could help the next woman.

All the details

Every number behind this page.

Who was in the studies

19,050 people in 74 studies

7,474 womenmiddle line = equal numbers11,576 men

Race

  • White73.9%
  • Black / African American14.4%
  • Asian4.8%
  • Other2.5%
  • Hispanic / Latina1.9%

Studies didn't say how many of the women were Black, Asian or another race — only totals for everyone.

Hispanic or Latina
17.6%
Age 65 or older
31.8%
Studies with men only
2
Studies with women only
1
Rules that kept women out

Share of studies with each rule.

  • 57%

    No pregnant women

    Women who were pregnant could not join.

    See the exact rule
    “Pregnant Woman Or A Woman Of Childbearing Potential” NCT00546052
  • 55%

    No heart disease

    Women with heart disease, heart rhythm problems or a past heart attack were turned away.

    See the exact rule
    “Patient With Symptomatic Heart Failure (Classes 3 And 4)” NCT00546052
  • 38%

    No diabetes

    Women with diabetes were turned away.

    See the exact rule
    “A Patient With A Diagnosis Of Type II Diabetes Defined As Fasting Blood Glucose Level Equal Or Greater Than 7.0 Mmol/L Or A 2hpg In A 75-G OGTT Equal Or Greater Than 11.1 Mol/L Or Using Any Anti-Hyperglycemic Agents” NCT00546052
  • 32%

    No breastfeeding moms

    Women who were breastfeeding could not join.

    See the exact rule
    “Women of childbearing potential or who are breastfeeding” NCT00882440
  • 32%

    No cancer

    Women with current or past cancer were turned away.

    See the exact rule
    “Known Secondary Hypertension Of Any Aetiology (E.G., Uncorrected Renal Artery Stenosis, Malignant Hypertension, Or Hypertensive Encephalopathy)” NCT00546052
  • 23%

    No mental health conditions

    Women with depression, bipolar disorder or other mental health conditions were turned away.

    See the exact rule
    “…/metabolic (with the exception of non-insulin, dependent type 2 diabetes mellitus with HbA1c \< 9.5% at Screening), hematologic/oncologic (including an active malignancy other than basal cell carcinoma), neurologic and psychiatric diseases.” NCT00949884
What nobody checked

Share of studies that recorded each thing.

  • 0%
    Results shown separately for women
  • 0%
    Whether anyone was pregnant
  • 0%
    Whether women were past menopause
  • 14%
    Body weight (BMI)
  • 14%
    Hispanic / Latina or not
  • 60%
    Race
All 74 studies

Study titles and rules are shown in their original English.

StudyPhasepeople% women
Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)
NCT00090259
33,83429.8%
A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)
NCT00546052
31,71442.8%
Olmesartan Comparison to Losartan in Hypertensive Subjects
NCT00949884
494145.5%
SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)
NCT00739674
386351.8%
BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)
NCT00546754
378947.8%
Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome
NCT00429364
360839.8%
A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011)
NCT00882440
357633.5%
The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose
NCT00673790
453743.9%
Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients
NCT00734630
449139.9%
Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension
NCT00931710
448843.6%
Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients
NCT00922480
348530.9%
Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension
NCT00219141
346024.3%
MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension
NCT00888355
342835.3%
A Study to Investigate the Antihypertensive Efficacy of MK0954
NCT00887250
336635.8%
MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)
NCT01307046
333628.9%
Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399)
NCT01277822
433423.4%
MK-0954E Study in Participants With Hypertension (MK-0954E-357)
NCT01302691
332722.6%
An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))
NCT00568178
330642.5%
Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)
NCT01371747
230436.8%
The SCCS Polypill Pilot Trial
NCT02278471
230354.1%
The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study
NCT02676466
228952.6%
Obese Hypertension Study (0954-315)
NCT00289887
326159.8%
ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension
NCT03295734
222375.3%
Losartan Effects on Emphysema Progression
NCT02696564
422042.3%
An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension
NCT02235909
321554.9%
Losartan for Patients With COVID-19 Requiring Hospitalization
NCT04312009
220540%
Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients
NCT02188121
420439.7%
LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)
NCT00496834
420159.7%
Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial Hypertension
NCT02248961
317935.8%
Renoprotection in Early Diabetic Nephropathy in Pima Indians
NCT00340678
317072.9%
Angiotensin II Blockade for Chronic Allograft Nephropathy
NCT00067990
415338.6%
A Controlled Trial of Losartan in Posttraumatic Stress Disorder
NCT02709018
—14965.1%
Olmesartan Medoxomil Versus Losartan in Patients With Hypertension
NCT00857285
313043.1%
A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)
NCT00886600
312232%
Losartan for Patients With COVID-19 Not Requiring Hospitalization
NCT04311177
211749.6%
Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial
NCT02049307
21083.7%
Efficacy of Losartan in Preventing Progression of COPD
NCT00720226
410650%
Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337)
NCT00756938
310142.6%
Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy
NCT00446563
39027.8%
Study of Cardiovascular Disease and Obstructive Sleep Apnea
NCT01637623
28639.5%